|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0000618,
umls-concept:C0023449,
umls-concept:C0025677,
umls-concept:C0030705,
umls-concept:C0031928,
umls-concept:C0035647,
umls-concept:C0087111,
umls-concept:C0348016,
umls-concept:C0441994,
umls-concept:C0442027,
umls-concept:C0445550,
umls-concept:C1518932
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1995-6-8
|
|
pubmed:abstractText |
This trial evaluated the toxicity and preliminary efficacy of a repeated oral low dose (LD) methotrexate schedule with intravenous mercaptopurine infusions as intensification therapy for children with lower risk B-lineage acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS. From December 1986 to January 1991, 96 children with newly diagnosed, lower risk ALL were enrolled. Vincristine, L-asparaginase, and prednisone were used for remission induction. Age-based methotrexate was administered intrathecally (IT) for central nervous system (CNS) prophylaxis. An outpatient-based intensification treatment included LD methotrexate 30 mg/M2 every 6 hours for 5 doses, followed by intravenous mercaptopurine 1000 mg/M2 for 6 hours every 2 weeks for 12 courses. Leucovorin rescue was administered 48 hours after methotrexate treatment was begun. Maintenance therapy included standard daily oral mercaptopurine, weekly intramuscular methotrexate, and IT methotrexate every 12 weeks, for 2 years.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
75
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2623-31
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:7736409-6-Mercaptopurine,
pubmed-meshheading:7736409-Administration, Oral,
pubmed-meshheading:7736409-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7736409-Asparaginase,
pubmed-meshheading:7736409-B-Lymphocytes,
pubmed-meshheading:7736409-Central Nervous System Neoplasms,
pubmed-meshheading:7736409-Child,
pubmed-meshheading:7736409-Disease-Free Survival,
pubmed-meshheading:7736409-Female,
pubmed-meshheading:7736409-Humans,
pubmed-meshheading:7736409-Infusions, Intravenous,
pubmed-meshheading:7736409-Injections, Intramuscular,
pubmed-meshheading:7736409-Injections, Spinal,
pubmed-meshheading:7736409-Male,
pubmed-meshheading:7736409-Methotrexate,
pubmed-meshheading:7736409-Pilot Projects,
pubmed-meshheading:7736409-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:7736409-Prednisone,
pubmed-meshheading:7736409-Remission Induction,
pubmed-meshheading:7736409-Treatment Outcome,
pubmed-meshheading:7736409-Vincristine
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
|
|
pubmed:affiliation |
Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
